TDO2 + cancer-associated fibroblasts mediate cutaneous squamous cell carcinoma immune escape via impeding infiltration of CD8 + T cells
Cancer Immunology, Immunotherapy · 2025
DOI: 10.1007/s00262-024-03921-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2025. Verfasst von Fangqi Lu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Photomedicine, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, 200443, China. Hauptthemen laut MEDLINE: Cancer-Associated Fibroblasts, Skin Neoplasms, CD8-Positive T-Lymphocytes, Tryptophan Oxygenase. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China.
Abstract (Originalsprache)
Cutaneous squamous cell carcinoma (cSCC) is the second most common skin cancer, originating from the malignant proliferation of squamous epithelial cells. However, its pathogenesis remains unclear. To further explore the mechanisms underlying cSCC, we analyzed the data from one single-cell RNA sequencing study and discovered a significant upregulation of tryptophan 2,3-dioxygenase (TDO2) in the cancer-associated fibroblasts (CAFs). Nonetheless, the specific expression and potential biological significance of TDO2 in cSCC have not yet been reported. In this study, we confirmed that TDO2 is highly expressed in CAFs of cSCC. Clinical correlation analysis indicated that high TDO2 expression was significantly associated with poor tumor differentiation. Furthermore, increased TDO2 expression in cSCC correlated with reduced CD8 + T cell infiltration, suggesting its role in modulating immune responses. TDO2 inhibitors significantly reduced the size and number of tumors in mice and effectively increased CD8 + T cell infiltration. RNA sequencing analysis revealed that TDO2 inhibitors modulate immune cell activity and downregulate the PI3K-Akt signaling pathway. In summary, our study demonstrates that TDO2 + CAFs induce immune evasion by inhibiting CD8 + T cell infiltration in cSCC. Inhibiting TDO2 could enhance antitumor immune responses, providing a promising strategy to improve treatment outcomes in cSCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Photomedicine, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, 200443, China.
- Department of Pathology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, 200443, China.
- Institute of Photomedicine, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, 200443, China. zengqingyu2011@tongji.edu.cn.
- Institute of Photomedicine, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, 200443, China. glzhangtj@tongji.edu.cn.
Förderung
- National Natural Science Foundation of China
- National Key Research and Development Program of China
Zitieren
APA
Lu, F., Yan, G., Zhao, Z., Zheng, Z., Wu, Y., Wen, L., Liu, Y., Zeng, Q., & Zhang, G. (2025). TDO2 + cancer-associated fibroblasts mediate cutaneous squamous cell carcinoma immune escape via impeding infiltration of CD8 + T cells. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-024-03921-0
Vancouver
Lu F, Yan G, Zhao Z, Zheng Z, Wu Y, Wen L, et al. TDO2 + cancer-associated fibroblasts mediate cutaneous squamous cell carcinoma immune escape via impeding infiltration of CD8 + T cells. Cancer Immunology, Immunotherapy. 2025. doi:10.1007/s00262-024-03921-0
BibTeX
@article{Lu2025,
author = {Lu, Fangqi and Yan, Guorong and Zhao, Zijun and Zheng, Zhe and Wu, Yuhao and Wen, Long and Liu, Yeqaing and Zeng, Qingyu and Zhang, Guolong},
title = {TDO2 + cancer-associated fibroblasts mediate cutaneous squamous cell carcinoma immune escape via impeding infiltration of CD8 + T cells},
journal = {Cancer Immunology, Immunotherapy},
year = {2025},
doi = {10.1007/s00262-024-03921-0}
}
EUVIMED